Legochem Biosciences, Inc.

Abl Bio Inc.

Dae Hyuck Kang

Yong Zu Kim

Young Lag Cho

Kyu Man Oh

Hyun Jin Kwon

Sung Min Kim

Min Soo Kim

Chul Soon Park

Sung Ho Woo

Hyang Sook Lee

Chul-Woong Chung

Tae Kyo Park

Sang Eun Chae

Sung Yoon Baek

Joung Yul Yun

Hye Kyung Chang

Young Jae Yang

Soo Bong Ha

Ho Young Song

Ju Young Lee

Juhee Kim

Bora Lee

Jeiwook Chae

Jeung Hie Choi

Hyoung Rae Kim

Hye Jin Heo

Yangsoon Lee

Kyung Eun Park

Byungje Sung

Chang Sun Lee

Jinhyung Ahn

Kyungjin Park

Donghoon Yeom

Jaehyun Eom

Daehae Song

Jiseon Yoo

Hye Jin Kang

Ji Hye Oh

Yun-Hee Park

Kyuman Oh

Minji Park

Hyeun Joung Lee

Hyun Min Ryu

JinWon Jung

Ju Yuel Baek

Young-Jae Yang

Nara Han

Ji-Na You

Youngeun Hong

Jeung Soon Choi

Young Zu Kim

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

Substituted dihydroisoxazole derivatives useful as inhibitors of &#x3b2;-lactamases are provided. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.

Compositions and methods for inhibiting &#x3b2;-lactamase

Compositions and methods for inhibiting beta-lactamase

The present invention relates to novel cephalosporin derivatives represented by X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

Cephalosporin derivatives and pharmaceutical compositions thereof

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R, and Rare as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. Compounds of the present invention are effective ingredients for the broad spectrum of antibiotic resistance, exhibit low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

Growing community of inventors

Daejeon, South Korea

Dae Hyuck Kang